Sight Sciences (SGHT) awards CEO Paul Badawi a $1M RSU grant

Rhea-AI Filing Summary

Sight Sciences reported that President and CEO Paul Badawi received a grant of 154,560 restricted stock units on February 3, 2026 under the company’s 2021 Incentive Award Plan. The grant’s size is based on a $1,000,000 value divided by the stock’s closing price on the grant date.

The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on Badawi’s continued service. Following this award, he beneficially owns 6,180,400 shares of common stock, including 662,622 shares underlying unvested RSUs.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Badawi Paul

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	154,560	$0.00	--

Holdings After Transaction: Common Stock — 6,180,400 shares (Direct)

Footnotes (1)

1. Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2026 and continuing through December 31, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $1,000,000 divided by the closing price of the Common Stock on the grant date, which was February 3, 2026. Includes (i) 5,517,778 shares of Common Stock, and (ii) 662,622 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Badawi Paul

(Last) (First) (Middle)

C/O SIGHT SCIENCES, INC.

4040 CAMPBELL AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		A		154,560(1)	A	$0.00	6,180,400(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2026 and continuing through December 31, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $1,000,000 divided by the closing price of the Common Stock on the grant date, which was February 3, 2026.

2. Includes (i) 5,517,778 shares of Common Stock, and (ii) 662,622 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested.

	/s/Jeremy Hayden, Attorney-in-Fact for Paul Badawi	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Sight Sciences (SGHT) report for Paul Badawi?

Sight Sciences reported a grant of 154,560 restricted stock units to President and CEO Paul Badawi on February 3, 2026. The award is part of his equity compensation under the 2021 Incentive Award Plan and vests over four years in quarterly installments.

How is the size of Paul Badawi’s RSU grant at Sight Sciences (SGHT) determined?

The RSU grant size equals $1,000,000 divided by Sight Sciences’ common stock closing price on February 3, 2026. This formula fixed the award at 154,560 RSUs, each representing the right to receive one share of common stock upon vesting and settlement.

What is the vesting schedule for Paul Badawi’s new RSUs at Sight Sciences (SGHT)?

The 154,560 RSUs vest in 16 equal quarterly installments, starting March 31, 2026 and continuing through December 31, 2029. Vesting requires Paul Badawi to remain in service with Sight Sciences through each applicable vesting date for the corresponding tranche.

How many Sight Sciences (SGHT) shares does Paul Badawi beneficially own after this grant?

After the reported RSU grant, Paul Badawi beneficially owns 6,180,400 shares of Sight Sciences common stock. This total includes 5,517,778 actual shares plus 662,622 shares that will be issued upon vesting and settlement of unvested restricted stock units previously granted.

Is the reported Sight Sciences (SGHT) transaction a purchase or a compensation grant?

The transaction is a compensation grant of restricted stock units to Paul Badawi at a stated price of $0.00 per share. It reflects equity awarded under the 2021 Incentive Award Plan rather than an open-market stock purchase or sale by the executive.